Doccol是一家美國生物技術(shù)公司，從解決生物研究中的實(shí)際問題開始調整推進。2004年溝通協調，Doccol發(fā)現(xiàn)了實(shí)驗(yàn)性卒中研究的關(guān)鍵問題之一是卒中模型的質(zhì)量不一致帶來全新智能，因此通過提供標(biāo)準(zhǔn)化的封堵器效果，即硅橡膠涂層單絲支撐作用，用于大腦中動脈閉塞（MCAO）生產創效，為此提供了解決方案奮戰不懈。這些MCAO封堵器深受中風(fēng)科研人員的喜愛還不大，并被命名為“MCAO縫合線"高產。 我們精致的硅橡膠涂層單絲是專門為誘導(dǎo)MCAO腔內(nèi)燈絲模型而設(shè)計制造的，該模型已被廣泛用于體內(nèi)實(shí)驗(yàn)性腦卒中研究發揮作用。使用 Doccol MCAO 縫合線誘導(dǎo)卒中模型將通過減少不全部閉塞和顱內(nèi)出血的發(fā)生來提高模型質(zhì)量良好。使用Doccol MCAO縫合線，您將能夠?qū)崿F(xiàn)高度一致的梗死以及低死亡率銘記囑托。除了認(rèn)可的產(chǎn)品質(zhì)量外引領，Doccol還為MCAO縫合線提供了種類繁多的縫合線，旨在滿足中風(fēng)研究人員的各種需求示範。多年來應用前景，我們的MCAO縫合線一直被中風(fēng)研究人員優(yōu)選用于誘導(dǎo)中風(fēng)模型。據(jù)報道運行好，使用Doccol MCAO縫合線誘導(dǎo)MCAO模型能夠?qū)⒐Ｋ荔w積的標(biāo)準(zhǔn)偏差降低到其相應(yīng)平均值的5%; 這種建模方法正在成為確保MCAO模型最高質(zhì)量的新標(biāo)準(zhǔn)首次。欲了解更多信息，中國客戶請聯(lián)系美國Doccol在中國的總代理靶點(diǎn)科技統籌推進。

2010年方案，Doccol注意到大多數(shù)實(shí)驗(yàn)室進(jìn)行的微血管導(dǎo)管插入術(shù)對于血液檢測和藥物輸送都不方便。這些“微導(dǎo)管"有一個需要針頭連接的過渡管了解情況，當(dāng)壓力高時可能會斷裂深入，并且可能會意外刺入操作員的手指，然后才能連接到合成器重要的。這些導(dǎo)管也有很大的內(nèi)部容積開展研究，必須處理才能輸送藥物。Doccol 提供專門設(shè)計的微導(dǎo)管問題分析，用于提高嚙齒動物血液采樣培養、藥物輸送、小流速液體轉(zhuǎn)移和生理監(jiān)測的性能更加完善、質(zhì)量和生產(chǎn)率形式，其中需要侵入性血管通路。我們的微導(dǎo)管連接到工業(yè)標(biāo)準(zhǔn)的魯爾鎖或旋塞閥支撐作用，因此消除了過渡管和針頭連接日漸深入，也大大減少了內(nèi)部體積動力。Doccol 為所有常見部位的血管插管提供了足夠的微導(dǎo)管選擇，例如尾靜脈互動式宣講、股靜脈效高性、頸靜脈和臂靜脈和動脈，以及頸靜脈自動化。

在Doccol多年來致力于中風(fēng)研究期間提升，Doccol 還開始提供精心挑選的基本顯微手術(shù)工具和設(shè)備，并于 2019 年開發(fā)了其不同的基于 Arduino 的 PID 溫度控制器不折不扣。這些工具和設(shè)備可確保您的實(shí)驗(yàn)性中風(fēng)研究具有高質(zhì)量和高生產(chǎn)率支撐能力。

Doccol is a biotech company that started from solving real problems in biological research. In 2004, Doccol identified one of the key problems in experimental stroke research is the inconsistent quality of stroke models, and thence provided a solution for this by offerring standardized occluders, the silicone rubber-coated monofilaments,  for middle cerebral artery occlusion (MCAO). Those MCAO occluders  were liked very much by stroke reaearchers and given the name "MCAO sutures".  Our delicate silicone rubber-coated monofilaments are specially designed and manufactured for inducing the intraluminal filament model of MCAO, which has been widely used for in vivo experimental stroke studies. Using Doccol MCAO sutures for inducing stroke models will improve your model quality by reducing the occurrence of both the incomplete occlusion and the intracranial bleeding. With Doccol MCAO sutures, you will be able to achieve a highly consistent infarct as well as a low mortality rate. In addition to the super product quality, Doccol provides MCAO sutures with a great variety that was designed to meet the diverse demand from stroke investigators. For many years our MCAO sutures have been preferably selected by stroke investigators for inducing stroke models. Using Doccol MCAO sutures for inducing MCAO models has been reported to be able to reduce the standard deviation to 5% of its corresponding mean value as for infarction volume; and this modeling method is becoming a methodological new standard for ensuring the highest quality of MCAO models. For more information please read Doccol Made a Difference in Stroke Modeling.

In 2010, Doccol noticed that microvascular catheterization procedures performed in most laboratories are inconvinient for both blood testing and drug delivery. Those "microcatheters" have a transition tubing requiring a needle connection, which may break when pressure is high, and may accidentally puncture into the operator's finger, before it can be connected to a synringe. These catheters also have a large inner volume that has to be dealt with for drug delivery. Doccol offerred specially designed microcatheters for improving performance, quality and productivity in rodent blood sampling, drug delivery, small flow rate liquid transferring, and physiological monitoring, in which invasive vascular access is necessary. Our microcatheters are permanently connected to an industrial standard Luer lock or stopcock, therefore, eliminated the transitional tubing and needle connection and also dramatically reduced inner volume. Doccol provides sufficient choices of micro catheters for vascular cannulation in all common locations, such as the tail, femoral, carotid, and brachial veins and arteries, and also the jugular veins.

During years of our dedicated services in stroke research, Doccol also started to provide our carefully-selected essential microsurgical tools and devices, and in 2019 Doccol developed its unique Arduino-based PID temperature controllers. These essential tools and devices ensure your experimental stroke research with high quality and high productivity.

靶點(diǎn)科技（北京）有限公司（Target Technology (Beijing) Co.,Ltd.）深入開展，成立于2016年新創新即將到來，是由一群來自歐洲荷蘭的留學(xué)海歸和高校及研究所博士人員創(chuàng)辦的生物高科技公司合規意識。公司基于四個平臺技術(shù)TargoSome^®（脂質(zhì)體靶向技術(shù)）顯示，TargoChem^®（化合物靶向技術(shù)）不可缺少，TargoAnti^®（抗體靶向技術(shù)）和TargoNano^®（納米靶向技術(shù)）共同努力，研發(fā)了靶向細(xì)胞的遞送系統(tǒng)推動。

公司注重轉(zhuǎn)化醫(yī)學(xué)還不大，強(qiáng)化“Bench-to-Bedside"的基礎(chǔ)產(chǎn)品開發(fā)市場開拓。目前措施，靶點(diǎn)科技已經(jīng)成為單核巨噬細(xì)胞系統(tǒng)研究領(lǐng)域的樹立良好口碑，能夠給研究人員提供各種模擬人類疾病的動物模型的制備要落實好，公司團(tuán)隊對單核巨噬細(xì)胞系統(tǒng)有著深刻的認(rèn)識和理解緊密相關，從標(biāo)記，分離先進技術，富集培訓，純化，培養(yǎng)和細(xì)胞清除宣講手段，形態(tài)識別等提供一整套綜合解決方案重要工具。

基于對靶點(diǎn)科技（北京）有限公司的認(rèn)同，自2022年11月29日期全面闡釋，靶點(diǎn)科技被美國Doccol公司授權(quán)為中國總代理非常激烈。客戶通過靶點(diǎn)科技購買美國Doccol公司的產(chǎn)品引人註目，質(zhì)量可靠領域，渠道合法，售后無憂好宣講。大腦中動脈阻塞(MCAO)造模是研究缺血性腦卒中的經(jīng)典動物模型註入新的動力，Doccol是MCAO造模國際廣泛使用的栓線品牌，文獻(xiàn)數(shù)以萬計。

靶點(diǎn)科技始終秉承“Bench to Bedside"的出發(fā)點(diǎn)去完善，“專業(yè)⁺專注⁺"的服務(wù)宗旨橋梁作用，以“Hit Your Target^®"為目標(biāo)， 竭力為客戶提供“Proven and Published^®"的一攬子綜合解決方案求索，將為實(shí)現(xiàn)這一美好愿景而努力奮斗。